Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10489778 | Journal of Engineering and Technology Management | 2005 | 17 Pages |
Abstract
This paper analyzes the consequences for the knowledge transfer and the organization of R&D of pharmaceutical companies after the acquisition of biotech companies. Based on four in-depth case studies, this paper comes to the conclusion that there is no systematic biotechnological know-how transfer from the biotech to the pharmaceutical company after the acquisition. Instead, the biotech companies remain independent and take over the role of centers of excellence for R&D within the pharmaceutical companies because that is the only way of preserving the innovative capabilities of the biotech company.
Related Topics
Social Sciences and Humanities
Business, Management and Accounting
Accounting
Authors
Lars Schweizer,